Fundraising Fox
i&i Biotech Fund
Venture capitalLuxembourg · Pre-Seed–Series A · 9 people tracked
Find your way into i&i Biotech Fund
Sign up to see every warm intro you have to i&i Biotech Fund
- Paths you didn't know you had: your email and LinkedIn already hold routes to the i&i Biotech Fund team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
i&i Bio backs Europe's next wave of early-stage life science startups that address unmet medical needs through strong science and a competitive edge. It seeks founders with a clear edge and ambition to take innovations global, and is willing to engage very early in a company's journey. The fund supports business creation from around €150k, with a sweet spot between €0.5M and €2M, and reserves possible follow-on funding for its best-performing portfolio. Its primary geographic focus is Central and Eastern Europe, though it works with teams across Europe. As a life sciences investor, it concentrates on drug discovery, medtech, diagnostics, and AI verticals.
Source: firm website, verified Sep 27, 2026.
Team · 9 people
from the firm's website & curated & public directories
What they invest in
from 17 of 19 portfolio companiesBiotech ×16Healthtech ×9Deep Tech ×6Medical Devices ×5AI & Machine Learning ×4Hardware ×2New Materials ×2Digital Health ×1
HQs:United States×3Czechia×2Germany×2United Kingdom×2Netherlands×2Spain×1
Who they back
founder profiles across 9 portfolio companiesFounding team size:solo founder×32 founders×23 founders×24+ founders×2
Investments · 19 tracked
founders shown can be your intro pathBy year:2023 · 32022 · 25 dated
Sophomer is a Czech biotech company developing in vitro diagnostics (IVD) products, working in partnership with academic labs on the design and synthesis of new polymers.
BiotechHealthtechMedical DevicesNew Materials
Martin Burkhard(Founder & Managing Director – CEO, Operations & Development)Jan Plicka(Founder and Inventor & Managing Director – R&D)Jiří Moos(Founder and Inventor & Managing Director, Business Development)inTomáš Etrych(Founder and Inventor & Sophomer's Partner Lab)Libor Kostka(Founder and Inventor & Sophomer's Partner Lab)Vladimír Šubr(Founder and Inventor & Sophomer's Partner Lab)
Co-investorsBiotech Investments S.R.O
Antiverse is a techbio company that uses machine learning and cell line engineering to design de novo antibody therapeutics against difficult targets such as G-protein coupled receptors and ion channels.
AI & Machine LearningBiotechDeep TechCardiff, GB
Ben H.(Founder)in
Co-investorsBig Wealth InternationalCambridge Angels groupDeep Science VenturesDOMiNO VenturesFuture Planet CapitalInnospark Ventures+2 more
CasInvent Pharma develops pharmaceutical solutions, currently raising Series A funding through a crowdfunding campaign.
BiotechHealthtech
Alexander Scheer(CEO)in
Co-investorsBiotech Investments S.R.OJIC VenturesKhanu
Delta Development Team manufactures temperature-controlled medical transport and storage devices, including smart blood coolers and autonomous refrigeration units, for healthcare facilities and blood banks.
HardwareHealthtechLogistics & Supply ChainMedical Devices
Co-investorsAggie Angel NetworkAZ Venture Capital Inc.Central Texas Angel NetworkSymbiotic VenturesOost NL
Delta Life Science develops the inQuiQ, a label-free biosensing instrument that uses integrated photonics to measure biomolecular binding affinity and kinetics (KD, ka, kd) in real time from small sample volumes.
BiotechDeep TechHardware
Co-investorsOost NL
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardJonathan Leff(Director)Robert Jackson(Director)
Co-investorsBiotech Investments S.R.OOUP (Osage University Partners)Deerfield Management CompanySofinnova Ventures
Enzyre develops a handheld diagnostic device that performs multiple blood coagulation assays in parallel to identify bleeding causes at the point of care.
BiotechDeep TechDigital HealthHealthtechMedical DevicesEindhoven, NL
Wim van den Broek(CEO)inWaander(CSO)
Co-investorsNovalis BiotechOost NLTakeda Ventures
Heartbeat.bio develops cardiac chamber models (Cardioids) and an assay suite that characterize heart disease phenotypes at structural, functional, and molecular levels.
BiotechDeep TechHealthtech
Michael Krebs(Founder)Pablo Hofbauer(Founder)
Co-investorsaws Gründungsfonds
iQure Pharma is a biopharmaceutical company developing therapies aimed at restoring glutamate balance and reducing excitotoxicity in neurological disorders with high unmet need.
BiotechHealthtechSkillman, US
Peter Schiemann(Founder)inPawel Zolnierczyk(Executive Officer)in
Co-investorsKeiretsu ForumVentura BioMed Investors
KyDo Therapeutics is a preclinical-stage biotechnology company developing novel covalent-allosteric small molecule inhibitors intended to become best-in-class oncology drugs.
AI & Machine LearningBiotechDortmund, DE
Co-investorsKhanu
LAM-X develops advanced nanofiber and polymer materials, including light-activated antimicrobial textiles and Western Blot membranes, for applications in medical devices, food packaging, crop protection, water filtration, and life science research.
BiotechMedical DevicesNew MaterialsZlatníky-Hodkovice, CZ
Nanoligent is a biotech spin-off of the Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau that uses protein engineering and nanobiotechnology to develop targeted drug therapies, with a first cancer candidate targeting the CXCR4 receptor to limit tumor growth and metastasis.
BiotechDeep TechMedical DevicesBarcelona, ES
Dr. A. Villaverde(Founder)Dr. E. Vázquez(Founder)Dr. R. Mangues(Founder)Dr. M. Rodríguez(Founder)
Co-investorsInveready Technology Investment GroupItalian Angels for GrowthClave Capital
Sampling Human develops systems to generate actionable insights from individual biology using cellular-resolution data collection technologies.
AI & Machine LearningBiotechHealthtech
Daniel Georgiev(Co-Founder, CEO, and Board Member)inHynek Kasl(Co-Founder and Head of Engineering)inMartin Cienciala(Co-Founder and Head of Innovation)in
Co-investorsB3 HoldingBiotech Investments S.R.O
T-CURX is a venture-backed biotechnology company developing autologous CAR-T cell therapies using proprietary non-viral technologies, including in vivo and bedside-manufactured CAR-T approaches based on T cell-targeted LNP delivery of Sleeping Beauty transposon vectors.
BiotechHealthtechWürzburg, DE
Michael Hudecek(Co-founder)Christoph Rader(Co-founder & Member of the Scientific Advisory Board)Ulf Grawunder(Co-founder & CEO)in
Co-investorsHighlight CapitalBioMedPartnersBayern Kapital
Ternary develops AI-driven drug discovery technology focused on targeted protein degradation and induced proximity platforms.
AI & Machine LearningBiotechDeep Tech
Chris Tame(CEO & Co-Founder)inAndrew Potterton(CTO & Co-Founder)in
Co-investorsDaphniPace VenturesUK Innovation & Science Seed Fund
Vasa Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics that target the pathophysiology of cardiovascular aging.
BiotechLongevity
Co-investorsElma VenturesNuFund Venture Group
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Captain T Cell GmbHCeleris Therapeutics
Portfolio news
latest coverage across their companiesT-CURX · uni-wuerzburg.de · Dec 17, 2025
Nanoligent · siliconcanals.com · Oct 10, 2025
KyDo Therapeutics · tu-dortmund.de · Sep 17, 2025
Frequently asked questions
- How many investments has i&i Biotech Fund made?
- i&i Biotech Fund has 19 tracked investments.
- What stage does i&i Biotech Fund invest at?
- i&i Biotech Fund invests at the Pre-Seed, Seed, Series A stages.
- What is i&i Biotech Fund's typical check size?
- i&i Biotech Fund typically writes checks of $150K – $2M.
- What sectors does i&i Biotech Fund focus on?
- i&i Biotech Fund focuses on AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is i&i Biotech Fund located?
- i&i Biotech Fund is headquartered in Luxembourg, LU.
- Who does i&i Biotech Fund co-invest with?
- i&i Biotech Fund most often shares deals with Biotech Investments S.R.O, Khanu, UK Innovation & Science Seed Fund, among 26 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.